FDA aims to pull Shire's blood pressure drug from the market

08/16/2010 | Wall Street Journal, The

The FDA is seeking to withdraw Shire's ProAmatine from the market because the drugmaker failed to conduct follow-up trials to demonstrate the drug's clinical benefit in patients with orthostatic hypotension. The treatment, generically known as midodrine hydrochloride, received accelerated approval in 1996.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ